CAMP
NASDAQ HealthcareCAMP4 Therapeutics Corporation - Common Stock
Biotechnology
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
๐ Market Data
| Price | $5.00 |
|---|---|
| Volume | 560,121 |
| Market Cap | 313.77M |
| RSI (14-Day) | 70.7 Overbought |
| 200-Day MA | $4.47 |
| 50-Day MA | $4.08 |
| 52-Week High | $7.75 |
| 52-Week Low | $1.41 |
| Forward P/E | -6.29 |
| Price / Book | -384.62 |
๐ฏ Investment Strategy Scores
CAMP scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (82/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CAMP in your text
Paste any article, transcript, or post โ the tool will extract CAMP and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.